Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study of its lead product, dalbavancin, a long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
55127
Durata Therapeutics initiates Phase 3 study of dalbavancin for the treatment of acute bacterial skin and skin structure infections
136418
Roche to strengthen global leadership position in oncology, to expand therapeutic areas
161739
New approach to treating high blood pressure
49985
Endosense launches TOCCATA clinical study
67145
Tamil Nadu to introduce regenerative medicine in veterinary care
128376
ChromeMate® reduces vascular inflammation
147662
Galenica's kidney drug meets endpoint in trial
65626
Drug prevents infections in dialysis patients
57730
Novartis drug helps patients with severe childhood arthritis
58512
Ranbaxy launches generic versions of Atorvastatin in Italy, Sweden and the Netherlands
99312
New injectable hydrogel repairs damage after heart attack
82081
Estée Lauder brand breaks new ground in skincare science
38108
Drug for bones helps keep breast cancer from spreading
69958
Alimera Sciences resubmits new drug application
9172
Madico announces suite of antimicrobial laminates
115795
Researchers identify new drug target for heart failure
142553
Glenmark starts Phase-IIb human trials of Revamilast molecule